Category: by country

Reuters removes story on gender confirmation surgery because firm mistakenly released data

Reuters has removed a story about gender confirmation surgery, saying it included problematic data.

The public relations firm representing the American Society of Plastic Surgeons (ASPS) — which generated the data in the report  — took responsibility, saying it supplied Reuters with data the ASPS did not want released.

Yesterday, Reuters pulled its version of a widely-reported story about an increase in such surgeries in the U.S. (Later, it pulled the withdrawal notice as well, only to make it reappear at a different URL.)

The story, originally posted just after midnight yesterday, reported a 19 percent increase in those procedures from 2015 to 2016, based on data provided the American Society of Plastic Surgeons (ASPS). Around 1 pm US Eastern time that day, Reuters put up a withdrawal notice in place of the original story:

Continue reading Reuters removes story on gender confirmation surgery because firm mistakenly released data

Researchers mistakenly administer three-fold higher dose of anesthesia

Researchers have retracted a 2016 paper after discovering that they accidentally administered three times the reported dose of anesthesia to rats.

In the Experimental Physiology paper, the authors set out to mathematically map how rats’ blood pressure changes under different conditions, which required the rats to be anesthetized. But their findings were called into question when they found the rats had received a much higher concentration of anesthesia than intended. According to the notice, this higher dose compromised the “objectives of the experiment.”

The corresponding author Karol Ondrias, from the Institute of Molecular Physiology and Genetics at the Slovak Academy of Sciences in Bratislava, told us how the dosing error occurred: Continue reading Researchers mistakenly administer three-fold higher dose of anesthesia

Ex-PhD candidate sues advisor, school: Colorado prof “poisoned the well” after research dispute

A former University of Colorado Boulder graduate student is suing his ex-advisor for defamation after being shooed out midway through his doctoral program.

Robert Roscow says he had to leave CU Boulder’s department of Ecology and Evolutionary Biology (EBIO) in the fall of 2016 with only a master’s degree after fish evolution researcher David Stock dropped him as a student. Their relationship deteriorated following a dispute about whether another student should perform experiments Roscow considered to be essential to his dissertation.

Once dropped, Roscow was offered the chance to find another advisor, but never did. In his complaint, filed April 25 in Boulder County District Court, Roscow claims he has evidence that Stock “poisoned the well” by badmouthing him in email and in person to other professors, ultimately preventing Roscow from completing his degree.

As first reported by BusinessDen, Roscow is also suing CU Boulder for a breach of contract and for failing to “provide [him] with the reasonable opportunity to pursue his PhD,” among other allegations. 

CU Boulder declined to elaborate on the case. Chief Spokesperson Ryan Huff told us:

Continue reading Ex-PhD candidate sues advisor, school: Colorado prof “poisoned the well” after research dispute

Denmark to institute sweeping changes in handling misconduct

In six weeks, new policies for handling misconduct in Denmark will go into effect, which alter the definition of misconduct and establish clear policies for who handles such allegations.

Starting July 1, research misconduct will be limited to how it’s typically defined elsewhere — fabrication, falsification, and plagiarism (the previous definition included serious breaches of good scientific practices). All such allegations will be investigated by a central body, The Board for the Prevention of Scientific Misconduct — not at the institutions where the allegations are focused, as it has been in the past. Institutions, however, will remain responsible for investigating allegations of so-called Questionable Research Practices (QRPs) — such as only reporting data that support your hypothesis — and must publicize their policies for handling (QRPs).

The Board for the Prevention of Scientific Misconduct will replace the Danish Committees on Scientific Dishonesty (DCSD).

You can read the press release from the Ministry of Higher Education and Science here. We translated it into English, here.

Continue reading Denmark to institute sweeping changes in handling misconduct

Four in 10 biomedical papers out of China are tainted by misconduct, says new survey

Chinese biomedical researchers estimate that 40% of research in their country has been affected in some way by misconduct, according to a new survey.

The authors are quick to caution against putting too much stock in this figure due to the subjective nature of the survey, published in Science and Engineering Ethics. The estimates also spanned a wide range, with a standard deviation of ±24%. But they say that the responses to this question and others on the survey suggest that scientists in the region feel academic misconduct remains a major problem that authorities have failed to adequately address. (Indeed, a recent analysis from Quartz using Retraction Watch data showed that researchers based in China publish more papers retracted for fake peer reviews than all other countries put together.)

The survey was designed by employees at Medjaden, a Hong Kong-based editing company that assists mainland Chinese biomedical researchers publishing in English-language journals. They invited all of their registered users by email to complete two surveys—roughly 10,000 users in 2010 and 15,000 in 2015. Like most online surveys, this one had a low response rate—around 5%, so caveats about sampling bias apply.

Study co-author Hua He, who is also Medjaden’s CEO, said:

Continue reading Four in 10 biomedical papers out of China are tainted by misconduct, says new survey

Could bogus scientific results be considered false advertising?

Could a scientific paper ever be considered an advertisement?

That was the question posed to a Tokyo court, in a criminal case where prosecutors argued — at the behest of Japan’s ministry of health — that a peer-reviewed paper containing faked data should be considered “fraudulent or exaggerated advertising” under that country’s laws.

In that case, however, the argument didn’t work. In March, the court decided that a fraudulent paper was not false advertising, allowing a pharmaceutical researcher at a Novartis subsidiary to escape jail time. The decision also cleared Novartis of charges and helped the company avoid a ¥4 million ($35,373 USD) fine.

According to an article in The Japan Times, the presiding judge Yasuo Tsujikawa said:

Continue reading Could bogus scientific results be considered false advertising?

Gender-based violence researcher now up to 10 retractions for plagiarism

A publisher has retracted all of the papers it published by a researcher in Nigeria, citing plagiarism.

The papers, all about terrorism and gender-based violence, were written by Oluwaseun Bamidele. The journal editors and the publisher, Taylor & Francis, decided to retract nine papers by Bamidele because of the overlap to other works — which he also failed to reference.

Bamidele — who also lost a paper on Boko Haram for the same reason — told us he didn’t learn about what constitutes plagiarism until his graduate studies, after he’d already written the now-retracted manuscripts:

Continue reading Gender-based violence researcher now up to 10 retractions for plagiarism

Journal retracts paper eight months after U.S. Feds announce findings of misconduct

In August, the U.S. Office of Research Integrity announced that a former postdoctoral fellow at the National Human Genome Research Institute (NHGRI) doctored data in two published papers.

It took one journal a little longer than five months to remove the researcher’s name from the co-author list, and replace one figure.

It took the second journal more than eight months to retract the paper.

Here’s the notice for “A BLOC-1 Mutation Screen Reveals that PLDN Is Mutated in Hermansky-Pudlak Syndrome Type 9,” published by the American Journal of Human Genetics (AJHG):

Continue reading Journal retracts paper eight months after U.S. Feds announce findings of misconduct

First author objects to retraction (his fourth) in chemistry journal

The first author of a 2013 chemistry paper is objecting to his co-authors’ decision to retract the paper, which contains duplicated figures.

We recently encountered a similar scenario with papers by first author Khalid Mahmood. In late 2015, Mahmood lost three papers in the journal ACS Applied Materials & Interfaces over duplicated images. One of the notices also indicated that the figures had “been published elsewhere and identified with different samples” — the same language used in the notice of the most recent retraction, in Journal of Materials Chemistry C.

Mahmood performed the work on the papers at Korea Advanced Institute of Science and Technology (KAIST), along with his two co-authors, Seung Bin Park and Hyung Jin Sung (also co-authors on two of the retracted papers in ACS Applied Materials & Interfaces).

Seung Bin Park, who is dean of the College of Engineering at KAIST, told us: Continue reading First author objects to retraction (his fourth) in chemistry journal

Journal: Here’s why we didn’t retract this duplicated paper

Here’s something we don’t see every day: A journal explains in an erratum notice why it chose not to retract a paper that contains data published elsewhere.

According to the Journal of Business and Psychology, the authors violated the journal’s transparency policy by failing to disclose that they’d used the same data in their 2014 in three others. However, the editors ultimately concluded the current paper was different enough from the other three to save it from being retracted.

Here’s the erratum: Continue reading Journal: Here’s why we didn’t retract this duplicated paper